欧狄沃格勒保卫战

昨天施大爷算是小小的扬眉吐气了一把，先是O+Y拿下一线恶性胸膜间皮瘤(MPM，虽然很rare)，然后是O联合卡博替尼拿下一线mRCC(虽然也...)

CheckMate-743：O 3mpk q2w + Y 1mpk q6w 对比化疗（培美曲塞+铂）一线治疗恶性胸膜间皮瘤（MPM），显著提升主要终点OS。

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb (NYSE: BMY) today announced that CheckMate -743, a pivotal Phase 3 trial evaluating Opdivo ^® (nivolumab) in combination with Yervoy ^® (ipilimumab) in previously untreated malignant pleural mesothelioma (MPM) met its primary endpoint of overall survival (OS). Based on a pre-specified interim analysis conducted by the independent Data Monitoring Committee, Opdivo in combination with Yervoy resulted in a statistically significant and clinically meaningful improvement in OS compared to chemotherapy (pemetrexed and cisplatin or carboplatin).The safety profile of Opdivo plus Yervoy observed in the trial reflects the known safety profile of the combination.

MPM相对罕见，但预后较差，难以治愈，一线的OS一般小于1年，5年生存~10%，有个参考，之前2线治疗中O单药和O+Y的OS分别11.9和15.6mo

另外，CheckMate-9ER中，主要终点PFS和次要终点OS、ORR都满足：

PRINCETON, N.J. & ALAMEDA, Calif.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) and Exelixis, Inc. (NASDAQ: EXEL) today announced that CheckMate -9ER, a pivotal Phase 3 trial evaluating Opdivo ^® (nivolumab) in combination with CABOMETYX^® (cabozantinib) compared to sunitinib in previously untreated advanced or metastatic renal cell carcinoma (RCC), met its primary endpoint of progression-free survival (PFS) at final analysis, as well as the secondary endpoints of overall survival (OS) at a pre-specified interim analysis, and objective response rate (ORR). The safety profiles of Opdivo and CABOMETYX observed in the trial reflect the known safety profiles of the immunotherapy and tyrosine kinase inhibitor components in first-line RCC.